Bio-Path Holdings` Initial Phase I Data in Leukemia Clinical Trial Demonstrates That Its Neutral Lipid Delivery Technology Antisense Drug BP-100-1.01 (Liposomal Grb-2) is Well Tolerated with Activity Seen at Low Starting Dos